161 related articles for article (PubMed ID: 17542057)
1. Comparison of pharmacokinetics, efficacy and toxicity profile of gemcitabine using two different administration regimens in Chinese patients with non-small-cell lung cancer.
Wang LR; Liu J; Huang MZ; Xu N
J Zhejiang Univ Sci B; 2007 May; 8(5):307-13. PubMed ID: 17542057
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic study of gemcitabine, given as prolonged infusion at fixed dose rate, in combination with cisplatin in patients with advanced non-small-cell lung cancer.
Caffo O; Fallani S; Marangon E; Nobili S; Cassetta MI; Murgia V; Sala F; Novelli A; Mini E; Zucchetti M; Galligioni E
Cancer Chemother Pharmacol; 2010 May; 65(6):1197-202. PubMed ID: 20140616
[TBL] [Abstract][Full Text] [Related]
3. The efficacy and relationship between peak concentration and toxicity profile of fixed-dose-rate gemcitabine plus carboplatin in patients with advanced non-small-cell lung cancer.
Wang L; Wu X; Huang M; Cai J; Xu N; Liu J
Cancer Chemother Pharmacol; 2007 Jul; 60(2):211-8. PubMed ID: 17124596
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of gemcitabine and carboplatin in patients with advanced non-small-cell lung cancer.
Wang LR; Huang MZ; Zhang GB; Xu N; Wu XH
Cancer Chemother Pharmacol; 2007 Sep; 60(4):601-7. PubMed ID: 17549479
[TBL] [Abstract][Full Text] [Related]
5. A multicentre randomised phase II study of carboplatin in combination with gemcitabine at standard rate or fixed dose rate infusion in patients with advanced stage non-small-cell lung cancer.
Soo RA; Wang LZ; Tham LS; Yong WP; Boyer M; Lim HL; Lee HS; Millward M; Liang S; Beale P; Lee SC; Goh BC
Ann Oncol; 2006 Jul; 17(7):1128-33. PubMed ID: 16670205
[TBL] [Abstract][Full Text] [Related]
6. Gemcitabine administered as a short infusion versus a fixed dose rate in combination with cisplatin for the treatment of patients with advanced non-small cell lung cancer.
Pereira JR; Fein L; Del Giglio A; Blajman CR; Richardet E; Schwartsmann G; Orlando M; Hall BJ; West TM; van Kooten M
Lung Cancer; 2007 Oct; 58(1):80-7. PubMed ID: 17588704
[TBL] [Abstract][Full Text] [Related]
7. Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma.
Tempero M; Plunkett W; Ruiz Van Haperen V; Hainsworth J; Hochster H; Lenzi R; Abbruzzese J
J Clin Oncol; 2003 Sep; 21(18):3402-8. PubMed ID: 12885837
[TBL] [Abstract][Full Text] [Related]
8. Dose-finding, pharmacokinetic and phase II study of docetaxel in combination with gemcitabine in patients with inoperable non-small cell lung cancer.
Rebattu P; Quantin X; Ardiet C; Morere JF; Azarian MR; Schuller-Lebeau MP; Pujol JL
Lung Cancer; 2001; 33(2-3):277-87. PubMed ID: 11551423
[TBL] [Abstract][Full Text] [Related]
9. Fixed-dose rate infusion and standard rate infusion of gemcitabine in patients with advanced non-small-cell lung cancer: a meta-analysis of six trials.
Qiu MT; Ding XX; Hu JW; Tian HY; Yin R; Xu L
Cancer Chemother Pharmacol; 2012 Dec; 70(6):861-73. PubMed ID: 23053260
[TBL] [Abstract][Full Text] [Related]
10. A randomized phase II trial evaluating standard (50 mg/min) versus low (10 mg/min) infusion duration of gemcitabine as first-line treatment in advanced non-small-cell lung cancer patients who are not eligible for platinum-based chemotherapy.
Cappuzzo F; Novello S; De Marinis F; Selvaggi G; Scagliotti GV; Barbieri F; Maur M; Papi M; Pasquini E; Bartolini S; Marini L; Crinò L
Lung Cancer; 2006 Jun; 52(3):319-25. PubMed ID: 16630670
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of gemcitabine in Chinese patients with non-small-cell lung cancer.
Wang LR; Huang MZ; Xu N; Shentu JZ; Liu J; Cai J
J Zhejiang Univ Sci B; 2005 May; 6(5):446-50. PubMed ID: 15822162
[TBL] [Abstract][Full Text] [Related]
12. A multicenter phase II trial of vinorelbine plus gemcitabine in previously untreated inoperable (Stage IIIB/IV) non-small cell lung cancer.
Chen YM; Perng RP; Yang KY; Liu TW; Tsai CM; Ming-Liu J; Whang-Peng J
Chest; 2000 Jun; 117(6):1583-9. PubMed ID: 10858387
[TBL] [Abstract][Full Text] [Related]
13. [Peak concentration of gemcitabine at fixed-dose-rate and its hematological toxicity profile].
Wang LR; Zhang GB; Huang MZ
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2007 Jul; 36(4):391-5. PubMed ID: 17717833
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of fixed dose-rate gemcitabine in combination with carboplatin in chemonaive advanced non-small-cell lung cancer: a Cancer Therapeutics Research Group study.
Soo RA; Lim HL; Wang LZ; Lee HS; Millward MJ; Tok LT; Lee SC; Lehnert M; Goh BC
Cancer Chemother Pharmacol; 2003 Aug; 52(2):153-8. PubMed ID: 12750842
[TBL] [Abstract][Full Text] [Related]
15. Prolonged gemcitabine infusion in advanced non-small cell lung carcinoma: a randomized phase II study of two different schedules in combination with cisplatin.
Ceribelli A; Gridelli C; De Marinis F; Fabi A; Gamucci T; Cortesi E; Barduagni M; Antimi M; Maione P; Migliorino MR; Giannarelli D; Cognetti F
Cancer; 2003 Jul; 98(2):337-43. PubMed ID: 12872354
[TBL] [Abstract][Full Text] [Related]
16. A randomized study comparing two different schedules of administration of cisplatin in combination with gemcitabine in advanced nonsmall cell lung carcinoma.
Ricci S; Antonuzzo A; Galli L; Tibaldi C; Bertuccelli M; Lopes Pegna A; Petruzzelli S; Bonifazi V; Orlandini C; Franco Conte P
Cancer; 2000 Oct; 89(8):1714-9. PubMed ID: 11042565
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of a 2-h infusion of gemcitabine plus carboplatin as first-line chemotherapy for advanced non-small-cell lung cancer.
Xu N; Shen P; Zhang XC; Yu LF; Bao HY; Shi GM; Huang S; Chen J; Mou HB; Fang WJ
Cancer Chemother Pharmacol; 2007 Jan; 59(1):1-7. PubMed ID: 16614849
[TBL] [Abstract][Full Text] [Related]
18. A randomized phase II trial using two different treatment schedules of gemcitabine and carboplatin in patients with advanced non-small-cell lung cancer.
Masters GA; Argiris AE; Hahn EA; Beck JT; Rausch PG; Ye Z; Monberg MJ; Bloss LP; Curiel RE; Obasaju CK
J Thorac Oncol; 2006 Jan; 1(1):19-24. PubMed ID: 17409822
[TBL] [Abstract][Full Text] [Related]
19. Fixed-dose rate gemcitabine plus carboplatin in relapsed, platinum-sensitive ovarian cancer patients: results of a three-arm Phase I study.
Alvarez RD; Mannel R; García AA; Gallion HH; Lucci J; Kilgore LC; Numnum TM; Zou SX; Orlando M; Tai DF
Gynecol Oncol; 2009 Dec; 115(3):389-95. PubMed ID: 19800673
[TBL] [Abstract][Full Text] [Related]
20. Gemcitabine and metabolite pharmacokinetics in advanced NSCLC patients after bronchial artery infusion and intravenous infusion.
Alharbi AF; Kratzke RA; D'Cunha J; Maddaus MA; Sanghavi K; Kirstein MN
Cancer Chemother Pharmacol; 2019 Feb; 83(2):387-391. PubMed ID: 30542769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
